ENVALITH
キリンホールディングス株式会社 logo

Kirin Holdings Company, Limited

2503・Prime Market・Foods

Official website
キリンホールディングス株式会社 logo
Kirin Holdings Company, Limited2503

Business

Kirin Holdings is a pure holding company founded in 1907, with 164 consolidated subsidiaries and 26 equity-method affiliates under its umbrella. Its core business is the Alcoholic Beverages segment (revenue of ¥1,075,261 million), covering domestic and overseas beer, RTD, and low-alcohol beverages. This is complemented by three other segments: the Beverages segment (¥578,190 million), encompassing soft drinks and the North American Coca-Cola business; the Pharmaceuticals segment (¥496,826 million), a global specialty pharma business centered on Kyowa Kirin; and the Health Science segment (¥256,113 million), which includes FANCL and Blackmores. Its main customers are general consumers, medical institutions, and pharmacies in Japan and abroad, and it is characterized by multi-regional operations spanning Japan, Oceania, North America, and Asia.

Business Model

The company generates stable cash flow from its existing alcoholic beverages, soft drinks, and pharmaceuticals businesses, and runs a cycle of prioritizing reinvestment into the Health Science business, which is expected to command a high multiple. Each business integrates manufacturing and sales, with brand strength and technological capabilities (fermentation, biotechnology, Lactococcus lactis strain Plasma, etc.) serving as the source of competitive advantage. Toward 2028, the company assumes total operating cash flow generation of approximately ¥840,000 million, and has set a financial policy allocating approximately ¥440,000 million to capital expenditure and approximately ¥240,000 million to dividends.

Company Strengths

Consolidated business profit for FY2025 reached ¥251,800 million (up 19.3% year on year), marking a record high for the third consecutive year. Price revisions and cost control in the Alcoholic Beverages business, growth of focus products in the Pharmaceuticals business, and the turnaround to profitability in the Health Science business (from a business loss of ¥10,900 million in the previous year to a profit of ¥11,105 million) all contributed simultaneously.

Sales of products containing Lactococcus lactis strain Plasma exceeded ¥28.0 billion in full-year 2025 (up from over ¥23.0 billion the previous year). Overseas shipments of the bacterial strain increased approximately 50% year on year in sales value terms. Horizontal expansion into beverages, supplements, and skincare, along with global expansion into Taiwan, Australia, and Southeast Asia leveraging Blackmores' distribution channels, is underway.

In November 2025, ziftomenib (KOMZIFTI) received formal approval from the US FDA. In addition to expanding the number of countries where Crysvita and Poteligeo are launched, multiple Phase II/III trials are underway, including OTL-203, KK8398, and KHK4951. The Pharmaceuticals business maintains a high business profit margin of 20.6%, remaining a key pillar of group profit.

ENVALITH's Perspective

Business profit for Q1 FY2026 was ¥49,992 million, up 37.7% year-on-year, marking a strong start, yet the full-year business profit forecast remains unchanged at ¥235,000 million (down 6.7% year-on-year), implying an expected profit decline. The 1Q progress rate stands at only about 21.3%, and even accounting for seasonality, the conservatism of the full-year forecast stands out. Whether the high growth in the pharmaceuticals segment (1Q business profit up 79.5%) continues, and whether special factors such as impairment losses (1Q: ¥4,891 million) become concentrated in the second half, will be key to achieving the full-year target.

In Q1 FY2026, the company acquired treasury shares worth ¥8,394 million and retired treasury shares equivalent to ¥236,572 million. The equity attributable to owners of the parent ratio improved from 36.8% (end of 2025) to 38.7% (end of 1Q FY2026), and the gross D/E ratio also fell significantly from 0.94x to 0.71x. The improvement in capital efficiency, combined with the sale of Four Roses (recording ¥5,361 million in proceeds from the sale of subsidiary shares), is commendable, but the specificity of capital allocation to growth investments (pharmaceuticals and health science) following the divestiture will be key to future share valuation.

Other operating expenses in Q1 FY2026 surged to ¥11,948 million (up 85.3% year-on-year), of which impairment losses expanded significantly to ¥4,891 million (versus ¥255 million in the same period last year). Pharmaceutical pipeline risk has become evident, exemplified by the discontinuation of the clinical trial for rocatinlimab (KHK4083), and whether Kyowa Kirin's high growth can be sustained depends on development progress going forward. In addition, while foreign exchange (a strong Australian dollar and strong US dollar) is currently supporting performance as an external factor, attention should also be paid to the risk that a reversal toward yen appreciation could worsen the yen-translated results of overseas subsidiaries.

Growth Strategy

Aiming to simultaneously improve EPS and PER through the profitability and expansion of the Health Science business and the global expansion of the pharmaceuticals business

Expanding the revenue scale of the Health Science segment through the full consolidation of FANCL and the integration of Blackmores. Segment business profit for 1Q FY2026 grew rapidly to ¥6,027 million (+88.2% year-on-year), driven by continued domestic and overseas expansion of Lactobacillus Plantarum (Plasma Lactic Acid Bacteria) and ongoing revenue and profit growth for Blackmores in Oceania, Southeast Asia, and China.

Establishing new revenue sources through the expansion of launch countries for Crysvita and Poteligeo, and the U.S. approval of ziftomenib (KOMZIFTI). 1Q FY2026 Pharmaceuticals segment business profit expanded sharply to ¥17,156 million (+79.5% year-on-year). The company aims to accelerate global expansion toward a full-year revenue target equivalent to ¥520.0 billion (up 4.7% year-on-year).

In 1Q FY2026, the company conducted share buybacks of ¥8,394 million and retired treasury shares equivalent to ¥236,572 million, improving the gross D/E ratio from 0.94x to 0.71x. Combined with business portfolio optimization measures such as the divestiture of Four Roses, the company aims to improve ROE and EPS. A deposit of ¥21,611 million for share buybacks has already been recorded, suggesting further buybacks are anticipated.

Through the effects of price revisions on domestic beer-type products and improvements in brand mix (increasing the proportion of higher-value-added products), the business profit margin on a revenue basis excluding liquor tax improved from 7.7% in 1Q FY2025 to 9.7% in 1Q FY2026. The company will continue to capture health-conscious demand through products such as the Hyoketsu® Sugar-Free series and non-alcoholic beverages.

Last updated: July 17, 2026